0000899243-17-016671.txt : 20170619 0000899243-17-016671.hdr.sgml : 20170619 20170619160533 ACCESSION NUMBER: 0000899243-17-016671 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20170615 FILED AS OF DATE: 20170619 DATE AS OF CHANGE: 20170619 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: AESCHENVORSTADT 36 CITY: BASEL STATE: V8 ZIP: 4051 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: AESCHENVORSTADT 36 CITY: BASEL STATE: V8 ZIP: 4051 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Subramanian Kala CENTRAL INDEX KEY: 0001682026 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 17918563 MAIL ADDRESS: STREET 1: C/O CRISPR THERAPEUTICS AG STREET 2: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-06-15 0 0001674416 CRISPR Therapeutics AG CRSP 0001682026 Subramanian Kala C/O CRISPR THERAPEUTICS, INC. 610 MAIN STREET CAMBRIDGE MA 02139 0 1 0 0 See Remarks Stock Options (Right to Buy) 14.43 2017-06-15 4 A 0 85000 0.00 A 2027-06-15 Common Shares 85000 85000 D This option was granted on June 15, 2017 with respect to 85,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning on July 15, 2017. Senior Vice President, Strategic Development and Operations /s/ Kala Subramanian 2017-06-19 EX-24 2 attachment1.htm EX-24 DOCUMENT
                               POWER OF ATTORNEY

        Know all by these presents, that the undersigned hereby constitutes and
appoints each of Marc Becker, Michael Esposito and Robert E. Puopolo, signing
singly, the undersigned's true and lawful attorney-in-fact to:

          (1)   execute for and on behalf of the undersigned, in the
                undersigned's capacity as an officer and/or director of CRISPR
                Therapeutics AG (the "Company"), (i) Form ID, including any
                attached documents, to effect the assignment of codes to the
                undersigned to be used in the transmission of information to the
                United States Securities and Exchange Commission using the EDGAR
                System, and (ii) Forms 3, 4 and 5 and amendments thereto in
                accordance with Section 16(a) of the Securities Exchange Act of
                1934, as amended, and the rules thereunder;

          (2)   do and perform any and all acts for and on behalf of the
                undersigned which may be necessary or desirable to complete and
                execute any such Form 3, 4 or 5 and amendments thereto and
                timely file such form with the United States Securities and
                Exchange Commission and any stock exchange or similar authority;
                and

          (3)   take any other action of any type whatsoever in connection with
                the foregoing which, in the opinion of such attorney-in-fact,
                may be of benefit to, in the best interest of, or legally
                required by, the undersigned, it being understood that the
                documents executed by such attorney-in-fact on behalf of the
                undersigned pursuant to this Power of Attorney shall be in such
                form and shall contain such terms and conditions as such
                attorney-in-fact may approve in such attorney-in-fact's
                discretion.

        The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this Power of Attorney and the
rights and powers herein granted. The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934, as amended. The undersigned hereby agrees to indemnify the
attorney-in-fact and the Company from and against any demand, damage, loss, cost
or expense arising from any false or misleading information provided by the
undersigned to the attorney-in-fact.

        This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.  This Power of Attorney may be filed with the
United States Securities and Exchange Commission as a confirming statement of
the authority granted herein. This Power of Attorney supersedes any prior power
of attorney in connection with the undersigned's capacity as an officer and/or
director of the Company.  This Power of Attorney shall expire as to any
individual attorney-in-fact if such attorney-in-fact ceases to be an executive
officer of, or legal counsel to the Company.

        IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of July 18, 2016.


                                                      /s/ Kala Subramanian
                                                --------------------------------
                                                            Signature


                                                         Kala Subramanian
                                                --------------------------------
                                                            Print Name